Results for tag: "Complement Component 5"

The Complement Component 5 market is a subset of the larger Immune Disorders Drugs market. It is focused on drugs that target the complement component 5 (C5) protein, which is a part of the complement system, a part of the innate immune system. C5 inhibitors are used to treat a variety of immune-mediated diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis. These drugs work by blocking the activity of C5, which helps to reduce inflammation and other symptoms associated with these diseases. The Complement Component 5 market is a rapidly growing segment of the Immune Disorders Drugs market, with many companies developing new drugs to target C5. Some of the major players in this market include AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more